FDA approves Pembrolizumab for patients with recurrent or metastatic HNSCC with disease progression on or after Platinum-containing chemotherapy

On 8 August, 2016, Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved pembrolizumab (KEYTRUDA®), the company’s anti-PD-1 (programmed death receptor-1) therapy, at a fixed dose of 200 mg every three weeks, for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy.

Read more from ESMO.